Climb Bio Doses First Patients in Budoprutug Phase 2 Trial, Expects Data in H2 2026.
ByAinvest
Thursday, Jan 8, 2026 7:10 am ET1min read
CLYM--
Climb Bio has dosed first patients in its budoprutug Phase 2 trial for pMN, with initial data expected in H2 2026. Dosing is ongoing in budoprutug Phase 1b/2a trials for ITP and Phase 1b trial for SLE, with regulatory clearance for SLE IND in China. The company has also dosed first patients in the CLYM116 Phase 1 healthy volunteer study. Anticipating a data-rich 2026, with initial readouts from all ongoing studies. Climb Bio has a strong financial position with a cash runway expected into 2028.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet